<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639743</url>
  </required_header>
  <id_info>
    <org_study_id>P030444</org_study_id>
    <nct_id>NCT00639743</nct_id>
  </id_info>
  <brief_title>PEITHO Pulmonary Embolism Thrombolysis Study</brief_title>
  <acronym>PEITHO</acronym>
  <official_title>Comparison Trial Evaluating Efficacy and Safety of Single i.v. Bolus Tenecteplase Plus Standard Anticoagulation as Compared With Standard Anticoagulation in Normotensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparin is the reference therapy for most patients with pulmonary embolism. Some patients
      with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the
      right ventricle have a higher mortality risk. It has been suggested that thrombolytic
      treatment, a drug that dissolves blood clots more rapidly, may reduce the mortality in those
      patients. The studies reported to date were unable to confirm or refute this hypothesis
      because the number of patients included in those studies is too low. The aim of the study is
      to compare thrombolytic treatment with heparin (which is the reference therapy for pulmonary
      embolism) in a large group of patients with sub-massive pulmonary embolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, double-blind, placebo-controlled, international, multicentre,
      parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus
      tenecteplase plus standard anticoagulation as compared with standard anticoagulation in
      normotensive patients with acute pulmonary embolism and with echocardiographic and laboratory
      evidence of right ventricular dysfunction.Patients suffering from acute pulmonary embolism
      (first symptoms occurring within 15 days) confirmed by lung scanning or a positive spiral
      computed tomogram, or a positive pulmonary angiogram, presenting with right ventricular
      dysfunction on echocardiography and tested troponin I or T positive will be included in the
      study if they have no exclusion criteria.Patients in the investigational group will receive:
      Ø Tenecteplase as a single body-weight (known or estimated) adjusted IV bolus administered
      over 5 - 10 seconds not later than 30 minutes after randomization, and not later than 2 hours
      after the diagnosis of RV dysfunction Weight (kg) Dose in mg Dose in units Dose in ml&lt;60 30
      mg 6000 U 6 ml&gt;60 to &lt;70 35 mg 7000 U 7 ml&gt;70 to &lt;80 40 mg 8000 U 8 ml&gt;80 to &lt;90 45 mg 9000 U
      9 ml&gt;90 50 mg 10000 U 10 mlØ and: concomitant therapy-Unfractionated heparin at a dose of 80
      IUxKg-1 as an intravenous bolus, followed by an infusion of 18 IUxKg-1xh-1, to be
      administered immediately after randomization in all patients for at least 48 hours following
      randomization. Beyond this period, intravenous UFH may be substituted with subcutaneous
      heparin (LMWH) treatment. The bolus will be omitted when heparin was started before
      randomisation.Patients in the control group will receive Ø placebo as a single body-weight
      (known or estimated) adjusted IV bolus administered over 5 - 10 seconds not later than 30
      minutes after randomization, and not later than 2 hours after the diagnosis of RV
      dysfunction. Weight (kg) Dose in ml&lt;60 6 ml&gt;60 to &lt;70 7 ml&gt;70 to &lt;80 8 ml&gt;80 to &lt;90 9 ml&gt;90
      10 mlØ and concomitant therapy with Unfractionated heparin
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure &lt; 90 mm Hg for at least 15 min or drop of syst</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic collapse within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed symptomatic pulmonary embolism recurrence within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death within 30 days</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total strokes (intra cranial haemorrhage or ischaemic stroke) within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding (other intracranial haemorrhage or ischaemic stroke)</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1005</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tenecteplase (group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo ( group B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo ( group B)</intervention_name>
    <description>placebo ( group B)</description>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenecteplase (group A)</intervention_name>
    <description>tenecteplase (group A)</description>
    <arm_group_label>group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Acute PE (first symptoms occurring 15 days or less before randomisation) confirmed by
             lung scan, or a positive spiral computed tomogram, or a positive pulmonary angiogram

          -  Right ventricular dysfunction confirmed by echocardiography or spiral computed
             tomography of the chest and a positive troponin I or T test

        Exclusion criteria:

          -  Haemodynamic collapse at presentation as defined above

          -  Known significant bleeding risk

          -  Administration of thrombolytic agents within the previous 4 days

          -  Vena cava filter insertion or pulmonary thrombectomy within the previous 4 days

          -  Uncontrolled hypertension defined as systolic BP &gt;180 mm Hg and/or diastolic BP &gt;110
             mm Hg at randomisation

          -  Treatment with an investigational drug under another study protocol in the previous 7
             days or greater, according to local requirements

          -  Previous enrolment in this study

          -  Known hypersensitivity to tenecteplase, alteplase, unfractionated heparin, or to any
             of the excipients

          -  Pregnancy, lactation or parturition within the previous 30 days. Women of childbearing
             age must have a negative pregnancy test or use a medically accepted method of birth
             control

          -  Known coagulation disorder (including vitamin K antagonists)

          -  Any other condition that the investigator feels would place the patient at increased
             risk if the investigational therapy is initiated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy MEYER, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux de Paris - Department of pneumology - European Hospital George Pompidou - Paris 15</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stavros Konstantinides, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology and Pulmonolog - Universitaetsmedizin Goettingen - 37099 Goettingen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vienna Medical University</name>
      <address>
        <city>Vienne</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital St. Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universistaetsklinik</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Democritus University of Thrace</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pécs</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Cardiologia, Policlinico S.Orsola-MaBologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Garcia de Orta</name>
      <address>
        <city>Almada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramon y Cajal Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004 Aug 10;110(6):744-9. Epub 2004 Jul 19.</citation>
    <PMID>15262836</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Heparin</keyword>
  <keyword>Thrombolytic therapy</keyword>
  <keyword>Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

